Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

May 16, 2023

SELL
$2.94 - $11.87 $41,748 - $168,554
-14,200 Closed
0 $0
Q1 2022

Apr 21, 2022

BUY
$4.38 - $18.78 $62,196 - $266,676
14,200 New
14,200 $71,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $47.9M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Virginia Retirement Systems Et Al Portfolio

Follow Virginia Retirement Systems Et Al and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virginia Retirement Systems Et Al, based on Form 13F filings with the SEC.

News

Stay updated on Virginia Retirement Systems Et Al with notifications on news.